Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Parliament Urges Increased Role For Generics And Biosimilars

Industry Welcomes Call For A ‘Greater Market Presence’ For Off-Patent Drugs

Executive Summary

A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.

You may also be interested in...



Off-Patent Industry Calls For Security Of Supply Legislation In EU

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislation. Without these, it says, additional cost containment measures for off-patent medicines under consideration by member states could threaten access by making production unsustainable for manufacturers.

Medicines For Europe Calls For Security Of Supply Legislation

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.

EU Must Stop Offshoring Of Essential Medicines, Say Trade Groups

Current EU policy discourages the domestic manufacturing of essential medicines, say Medicines for Europe and the European Fine Chemicals Group. The associations have called for “immediate, robust and ambitious” policy change to drive manufacturing back home.

Related Content

Topics

UsernamePublicRestriction

Register

GB151438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel